Skip to main content

eTheRNA in the race for a coronavirus vaccine

  • August 5, 2020

More than 1,5 years ago, Steven Powell became the CEO of the VUB spin-off eTheRNA. Since then, Powell has been working on an ambitious business plan for the company.  With the second round of capital where it raised €34M, eTheRNA wants to further develop its pipeline for cancer therapies and infectious disease treatments.

ETherNA recently formed a consortium with North American and European partners to develop the vaccine against COVID-19, based on its messenger RNA (mRNA) technology.

Read the interview with Steven Powell here